患者与代理人对例外知情同意研究的入组后观点:一项整合调查
本研究将10项纸笔调查整合入 Established Status Epilepticus Treatment Trial(ESETT),该试验为针对儿童和成人苯二氮䓬难治性癫痫持续状态的3种治疗随机试验。共调查317名患者和代理人,90%对入组表示同意或中立,10%不同意;27%不认同无前瞻性知情同意的入组。黑人参与者较白人、其他种族和未知种族更可能不认同无前瞻性知情同意的入组(分别为36% vs 23%、14%、14%)。参与者认为社区咨询最重要纳入患者(81%)、家属(65%)和癫痫风险人群(51%)。
要点
- 在317名患者和代理人中,90%对入组表示同意或中立,10%不同意。
- 27%的参与者不认同无前瞻性知情同意的入组。
- 黑人参与者不认同无前瞻性知情同意的入组比例为36%,高于白人23%、其他种族14%、未知种族14%。
- 参与者认为社区咨询最重要纳入患者(81%)、家属(65%)和癫痫风险人群(51%)。
适用人群与场景
- 纳入 Established Status Epilepticus Treatment Trial 的患者和代理人,该试验针对儿童和成人苯二氮䓬难治性癫痫持续状态。
研究设计与关键结果
- 研究为整合入 Established Status Epilepticus Treatment Trial 的10项纸笔调查,共317名患者和代理人参与。
- 90%的参与者对「我很高兴我/我的家人被纳入 Established Status Epilepticus Treatment Trial 研究」表示同意或中立,10%不同意。
- 27%的参与者不认同无前瞻性知情同意的入组。
- 黑人参与者较白人、其他种族和未知种族更可能不认同无前瞻性知情同意的入组(36% vs 23%、14%、14%)。
- 参与者认为社区咨询最重要纳入患者(81%)、家属(65%)和癫痫风险人群(51%)。
证据类型、等级与局限
- 证据类型:整合于随机试验的调查。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,研究结果进一步支持有针对性的社区咨询,重点关注与所研究疾病有关联的个体。
- 作者认为,未来研究应关注入组后阶段的沟通,尤其是对例外知情同意可能有顾虑的个体。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
STUDY OBJECTIVE: It is important for researchers interested in trials using the exception from informed consent to understand the views and experiences of enrolled individuals. Previous studies have shown that patient and surrogate attitudes are generally positive. These studies were small and did not include pediatric patients, and interviews were often conducted long after trial enrollment. This study sought to explore attitudes toward exception from informed consent in a larger sample and more contemporaneous setting.
METHODS: A 10-item paper-and-pencil survey was integrated into the Established Status Epilepticus Treatment Trial, a randomized trial of 3 treatments for benzodiazepine-refractory status epilepticus in pediatric and adult patients. Primary domains included attitudes toward trial enrollment, exception from informed consent, and community consultation. Simple descriptive statistics, χ2, and Fisher's exact tests were conducted.
RESULTS: Of 317 patients and surrogates, 90% agreed with or were neutral about the statement "I am glad that I/my family member was included in the Established Status Epilepticus Treatment Trial research study," whereas 10% disagreed. Twenty-seven percent disagreed with enrollment in the study without prospective consent. Black participants were more likely than white, other race, and unknown-race participants to disagree with enrollment without prospective consent (36% versus 23%, 14%, and 14%, respectively). Participants indicated that patients (81%), their families (65%), and those at risk for seizures (51%) were most important to include in community consultation.
CONCLUSION: This study aimed to explore attitudes toward exception from informed consent enrollment among participants at all sites in a large, multicenter exception from informed consent trial. General acceptance of trial enrollment was high; acceptance of exception from informed consent specifically was somewhat lower, especially among black participants. Our findings provide further support for targeted community consultation focusing on individuals with connections to the disease under study. Future research should focus on communication in the postenrollment period, especially with individuals who may have concerns about exception from informed consent.
参考来源
- Scicluna VM, Biros M, Harney DK, et al. Patient and Surrogate Postenrollment Perspectives on Research Using the Exception From Informed Consent: An Integrated Survey. Ann Emerg Med. 2020. PMID: 32446674. doi:10.1016/j.annemergmed.2020.03.017
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。